AlphaCentric Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

AlphaCentric Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25,500	Closed	-$2.95M	–	295
2023 Q3	$2.95M	Hold	25,500	–	–	1.67%	14
2023 Q2	$2.62M	Hold	25,500	–	–	1.46%	13
2023 Q1	$2.78M	Hold	25,500	–	–	1.92%	10
2022 Q4	$2.9M	Sell	25,500 -4,938	-16%	-$410K	2.87%	2
2022 Q3	$1.88M	Buy	+30,438	New	+$2.13M	1.93%	9
2021 Q4	$142K	Buy	1,320 +320	+32%	+$34.9K	0.04%	139
2021 Q3	$110K	Hold	1,000	–	–	0.03%	161
2021 Q2	$94K	Hold	1,000	–	–	0.03%	177
2021 Q1	$92K	Hold	1,000	–	–	0.03%	163
2020 Q4	$73K	Buy	1,000 +425	+74%	+$31.6K	0.03%	162
2020 Q3	$45K	Sell	575 -150	-21%	-$10.3K	0.02%	115
2020 Q2	$40K	Buy	+725	New	+$31K	0.02%	95

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AlphaCentric Advisors's HZNP Position: Q4 2023 in Review

AlphaCentric Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 25,500 shares — an estimated $2.95M sold.

AlphaCentric Advisors first reported a position in HZNP in Q2 2020 and held it in 12 quarters. The position peaked at $2.95M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

AlphaCentric Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
AlphaCentric Advisors sold 25,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $2.95M.
AlphaCentric Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 12 quarters.
AlphaCentric Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.95M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.